In line with these observations, in vitro studies demonstrated that targeting the MET pathway specifically interfered with the pancreatic CSC subpopulation, inducing apoptosis and reducing migration of resistant cells, and synergistically interacted with anti-tumor gemcitabine activity [111,112]. Here, MET is linked to neoplasm.